<SUBMISSION>
<ACCESSION-NUMBER>0001144204-05-009086
<TYPE>6-K
<PUBLIC-DOCUMENT-COUNT>3
<PERIOD>20050330
<FILING-DATE>20050330
<DATE-OF-FILING-DATE-CHANGE>20050330
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>pSivida LTD
<CIK>0001314102
<ASSIGNED-SIC>3826
<IRS-NUMBER>000000000
<STATE-OF-INCORPORATION>C3
<FISCAL-YEAR-END>0630
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>6-K
<ACT>34
<FILE-NUMBER>000-51122
<FILM-NUMBER>05711523
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
<PHONE>61 8 9226 5099
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>LEVEL 12 BGC CENTRE
<STREET2>28 THE ESPLANADE
<CITY>PERTH
<STATE>C3
<ZIP>6000
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v015244_6k.htm
<TEXT>
<HTML><HEAD>
<TITLE>
</TITLE>
</HEAD><BODY id=38 bgColor=#ffffff>
<DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>SECURITIES
AND EXCHANGE COMMISSION</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Washington,
D.C. 20549</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><STRONG>FORM
6-K</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT OF
FOREIGN ISSUER<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to Rule 13a-16 or 15d-16 of<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
Securities Exchange Act of 1934</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>For
the month of March 2005</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>Commission
File Number 000-5112</STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><STRONG>pSivida
Limited<BR></STRONG></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
of registrant&#8217;s name into English) </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level 12
BGC Centre<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28 The
Esplanade<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth WA
6000<BR></FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
of principal executive offices)</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
by check mark whether the registrant files or will file annual reports under
cover Form&nbsp;20-F or Form&nbsp;40-F). </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form 20-F
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Form
40-F </FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934.</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">o</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No
</FONT><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Wingdings">&#253;</FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If "Yes"
is marked, indicate below the file number assigned to the registrant in
connection with Rule&nbsp;12g3-2(b): 82- ___. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>SIGNATURE
</STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant,
pSivida Limited, has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized. </FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>
<TABLE cellSpacing=0 cellPadding=0 width="100%" align=center bgColor=#ffffff
border=0>
  <TR vAlign=top bgColor=#ffffff>
    <TD width="50%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="1%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD width="49%"><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD colSpan=2><FONT face="Times New Roman" size=2>pSivida
  Limited</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>&nbsp;<BR>&nbsp;</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD><FONT face="Times New Roman" size=2>Date:&nbsp;March 30,
2005</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>By:&nbsp;&nbsp;</FONT></TD>
    <TD><FONT face="Times New Roman" size=2>/s/&nbsp;Aaron Finlay</FONT></TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=1>&nbsp;</FONT></TD>
    <TD align=left>
      <HR align=left width="80%" color=#000000 noShade SIZE=2>
    </TD></TR>
  <TR vAlign=top bgColor=#ffffff>
    <TD colSpan=2><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD>
    <TD>
      <DIV><FONT face="Times New Roman" size=2>Aaron Finlay</FONT></DIV>
      <DIV><FONT face="Times New Roman" size=2><EM>Chief Financial Officer and
      Company Secretary</EM>&nbsp;</FONT></DIV></TD></TR></TABLE></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify><FONT size=2></FONT>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN style="PAGE-BREAK-AFTER: always">
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt" face="Times New Roman"></FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U></U></EM></STRONG></FONT>&nbsp;</DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=center><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG><EM><U>EXHIBIT
INDEX</U></EM></STRONG></FONT></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=justify>&nbsp;</DIV>
<DIV>
<TABLE cellSpacing=0 cellPadding=0 width="100%">
  <TR>
    <TD vAlign=top align=left width="15%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><STRONG>EXHIBIT
      99.1:</STRONG></FONT></DIV></TD>
    <TD vAlign=top align=left width="62%">
      <DIV
      style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
      align=left><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
      Reaches Milestone in Production Scale-up Process for BrachySil</FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><SUP>TM</SUP></FONT><FONT
      style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
      Cancer Therapy</FONT></DIV></TD></TR></TABLE></DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV>&nbsp;</DIV>
<DIV id=PGBRK style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
<DIV id=FTR>
<DIV id=GLFTR style="WIDTH: 100%" align=left><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>
<DIV id=PN>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center"><FONT
style="DISPLAY: inline; FONT-SIZE: 10pt" face="Times New Roman">-2-</FONT></DIV>
<DIV style="WIDTH: 100%; TEXT-ALIGN: center">
<HR color=#000000 noShade SIZE=2>
</DIV></DIV>
<DIV id=HDR>
<DIV id=GLHDR style="WIDTH: 100%" align=right><FONT
style="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
<DIV
style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1.25; MARGIN-RIGHT: 0pt"
align=left><BR></DIV>
<DIV></DIV></DIV></BODY></HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v015244_ex99-1.htm
<TEXT>
<HTML>
  <HEAD>
         <TITLE></TITLE>
  </HEAD>
  <BODY ID="38" BGCOLOR="#ffffff">
         <P><A NAME="page_1"></A></P>
         <P></P>
         <DIV>
                <TABLE WIDTH="100%">
                  <TR>
                         <TD></TD>
                         <TD ALIGN="RIGHT"><IMG SRC="logo.gif" WIDTH="142" HEIGHT="70"
                                BORDER="0"></TD>
                  </TR>
                  <TR>
                         <TD><B><FONT FACE="sans-serif">ASX/MEDIA RELEASE</FONT></B></TD>
                         <TD ALIGN="right"><B><FONT FACE="sans-serif">30</FONT></B><B><SUP>
                                <FONT FACE="sans-serif">th</FONT></SUP></B><B><FONT FACE="sans-serif"> March
                                2005</FONT></B></TD>
                  </TR>
                </TABLE></DIV>
         <P ALIGN="center"><B><FONT FACE="sans-serif" SIZE="5">pSivida Reaches
                Milestone in Production Scale-up Process for BrachySil&#153; Cancer
                Therapy</FONT></B></P>
         <P ALIGN="CENTER"><B><I><U><FONT FACE="sans-serif" SIZE="2">New facility
                will provide ultra-pure BioSilicon&#153; microparticles for future
                BrachySil&#153; production </FONT></U></I></B></P>
         <P><FONT FACE="sans-serif" SIZE="2">Global nanotechnology company pSivida
                Limited (</FONT><B><FONT FACE="sans-serif" SIZE="2">ASX:PSD, NASDAQ:PSDV,
                Xetra:PSI)</FONT></B><FONT FACE="sans-serif" SIZE="2"> is pleased to announce
                that it&#146;s UK manufacturing partner, Atomising Systems Ltd
                (&#147;ASL&#148;), has reached a key milestone in the manufacture of
                BrachySil&#153;, its lead product by completing construction of a state of the
                art dedicated cleanroom facility to GMP specifications at its Sheffield plant
                in the United Kingdom. ASL is a world leader in high temperature atomising
                technology.</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">The milestone achieved will enable
                pSivida to increase BrachySil&#153; production in support of both larger
                clinical trials for advanced liver cancer and new Phase IIa trials in a second
                cancer indication planned for later this year, and future commercialisation
                pSivida will use the dedicated facility to produce ultra-pure nano-structured
                BioSilicon&#153; microparticles doped with phosphorus: These microparticles are
                created using a specially developed melting process and water
                atomisation.</FONT> </P>
         <P><FONT FACE="sans-serif" SIZE="2">Following this process, the
                BioSilicon&#153; microparticles are activated to become BrachySil&#153;, i.e.
                the integral phosphorus is converted into its radioisotope form &#150; 32-P
                &#150; at AEA Technology QSA&#146;s Auriga Medical&#153; facility in
                Germany.</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">pSivida&#146;s Managing Director, Gavin
                Rezos, said, &#147;The development of this facility is important in the future
                development of BrachySil&#153; as a solid tumor cancer therapy. It forms one
                piece of the overall process for getting this exciting product through clinical
                trials to market and scale up production once regulatory approval is
                received.&#148;</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">BrachySil&#153; has recently shown
                excellent results in Phase II clinical trials as a radiotherapy for the
                treatment of inoperable primary liver cancer, where it is delivered directly
                into tumors without surgery, a procedure known as brachytherapy. </FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">The trials have shown no
                product-related side effects while also demonstrating significant tumor
                regression; up to 100% in some cases for smaller tumors. The ability of
                BrachySil&#153; to remain at the injection site is another significant outcome
                of the trial. </FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">pSivida expects to begin a
                dose-profiling study during 2005 and pivotal registration trials during 2005.
                These trials will be multi centre and will, involve patients in Asia, Europe
                and the US, to provide data to support planned registration of BrachySil&#153;
                in 2007 as an approved treatment for primary liver cancer.</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">pSivida also plans to expand the use of
                BrachySil&#153; as a treatment for a wider range of solid tumor indications. A
                Phase IIa clinical trial is scheduled to commence for a second cancer
                indication within the next year.</FONT> </P>
         <P><FONT FACE="sans-serif" SIZE="2">The brachytherapy market is currently
                over US$600 million per annum and is expected to exceed US$1 billion within the
                next few years (Bio-Tech Systems)</FONT><B><FONT FACE="sans-serif"
                SIZE="2">.</FONT></B><FONT FACE="sans-serif" SIZE="2"> BrachySil&#153; has the
                potential to significantly expand the current market size through its
                application to other cancers.</FONT></P>
         <P ALIGN="center"><B><FONT FACE="sans-serif" SIZE="2">-ENDS</FONT></B></P>
         <P ALIGN="center">&nbsp;</P>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>

                <DIV ID="PN" STYLE="PAGE-BREAK-AFTER: always">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt" FACE="Times New Roman"></FONT></DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR COLOR="#000000" NOSHADE="NOSHADE" SIZE="2"> </DIV></DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV><!--$$/page=-->
         <P><A NAME="page_2"></A></P>
         <DIV>
                <TABLE CELLSPACING="1" CELLPADDING="0" BORDER="0">
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><B><FONT FACE="sans-serif"
                                SIZE="2">Released by:</FONT></B>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%">&nbsp; </TD>
                  </TR>
                  <TR>
                         <TD COLSPAN="3">&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><B><FONT FACE="sans-serif"
                                SIZE="2">In Australia:</FONT></B>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><B><FONT FACE="sans-serif"
                                SIZE="2">In US:</FONT></B>&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><FONT FACE="sans-serif" SIZE="2">Josh
                                Mann</FONT>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><FONT FACE="sans-serif"
                                SIZE="2">Beverly Jedynak</FONT>&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><FONT FACE="sans-serif"
                                SIZE="2">Investor Relations</FONT>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><FONT FACE="sans-serif"
                                SIZE="2">President</FONT>&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><FONT FACE="sans-serif"
                                SIZE="2">pSivida Limited</FONT>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><FONT FACE="sans-serif"
                                SIZE="2">Martin E. Janis &amp; Company, Inc.</FONT>&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><FONT FACE="sans-serif" SIZE="2">Tel:
                                + 61 8 9226 5099</FONT>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><FONT FACE="sans-serif" SIZE="2">Tel:
                                312-943-1100 ext. 12</FONT>&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><U><FONT FACE="sans-serif"
                                COLOR="#0000ff" SIZE="2">joshuamann@psivida.com</FONT></U>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%"><U><FONT FACE="sans-serif"
                                COLOR="#0000ff" SIZE="2">bjedynak@janispr.com</FONT></U>&nbsp; </TD>
                  </TR>
                  <TR>
                         <TD COLSPAN="3">&nbsp; </TD>
                  </TR>
                  <TR VALIGN="bottom">
                         <TD NOWRAP="NOWRAP" WIDTH="45%"><B><FONT FACE="sans-serif"
                                SIZE="2">NOTES TO EDITORS:</FONT></B>&nbsp; </TD>
                         <TD WIDTH="2%">&nbsp; </TD>
                         <TD NOWRAP="NOWRAP" WIDTH="52%">&nbsp; </TD>
                  </TR>
                </TABLE></DIV><BR>
         <P><B><FONT FACE="sans-serif" SIZE="2">pSivida Limited </FONT></B><FONT
                FACE="sans-serif" SIZE="2">pSivida is a global nanotechnology company committed
                to the biomedical sector and the development of products in healthcare. The
                company&#146;s focus is the development and commercialisation of a modified
                form of silicon (porosified or nano-structured silicon) known as
                BioSilicon&#153;. As a new and exciting biocompatible material,
                BioSilicon&#153; offers multiple potential applications across the high growth
                healthcare sector, including controlled release drug delivery, targeted cancer
                therapies (including brachytherapy and localized chemotherapy), tissue
                engineering and orthopedics. Potential diagnostics applications are being
                developed through its subsidiary AION Diagnostics Limited.</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">pSivida owns the intellectual property
                rights to BioSilicon&#153; for use in or on humans and animals. The IP
                portfolio consists of 24 patent families, 26 granted patents and over 80 patent
                applications. The core patent, which recognises BioSilicon&#153; as a
                biomaterial was granted in the UK in 2000 and in the US in 2001.</FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">pSivida is listed on NASDAQ
                (</FONT><B><FONT FACE="sans-serif" SIZE="2">PSDV</FONT></B><FONT
                FACE="sans-serif" SIZE="2">), the Australian Stock Exchange (</FONT><B><FONT
                FACE="sans-serif" SIZE="2">PSD</FONT></B><FONT FACE="sans-serif" SIZE="2">) and
                in Germany on the Frankfurt Stock Exchange on the XETRA system (</FONT><B><FONT
                FACE="sans-serif" SIZE="2">German</FONT></B><FONT FACE="sans-serif" SIZE="2">
                </FONT><B><FONT FACE="sans-serif" SIZE="2">Symbol: PSI. Securities Code (WKN)
                358705</FONT></B><FONT FACE="sans-serif" SIZE="2">). pSivida&#146;s shares also
                trade in the United Kingdom on the OFEX International Market Service (IMS)
                under the ticker symbol </FONT><B><FONT FACE="sans-serif"
                SIZE="2">PSD</FONT></B><FONT FACE="sans-serif" SIZE="2">. </FONT></P>
         <P><FONT FACE="sans-serif" SIZE="2">The Company&#146;s strategic partner
                and largest shareholder is the QinetiQ group, the largest science and
                technology company in Europe. QinetiQ is the former UK government Defence
                Evaluation Research Agency and was instrumental in discovering
                BioSilicon&#153;. pSivida enjoys a strong relationship with QinetiQ having
                access to its cutting edge research and development facilities. For more
                information on QinetiQ visit </FONT><U><FONT FACE="sans-serif" COLOR="#0000ff"
                SIZE="2">www.qinetiq.com</FONT></U><FONT FACE="sans-serif" SIZE="2">.
                </FONT></P>
         <DIV>
                <TABLE>
                  <TR>
                         <TD NOWRAP="NOWRAP"><FONT FACE="sans-serif" SIZE="2">For more
                                information visit </FONT><U><FONT FACE="sans-serif" COLOR="#0000ff"
                                SIZE="2">www.psivida.com</FONT></U><BR></TD>
                  </TR>
                </TABLE></DIV>
         <P><FONT FACE="sans-serif" SIZE="1">This document contains forward-looking
                statements that involve risks and uncertainties. Although we believe that the
                expectations reflected in such forward-looking statements are reasonable at
                this time, we can give no assurance that such expectations will prove to be
                correct. Given these uncertainties, readers are cautioned not to place undue
                reliance on such forward-looking statements. Actual results could differ
                materially from those anticipated in these forward-looking statements due to
                many important factors including: our failure to develop applications for
                BioSilicon&#153; due to regulatory, scientific or other issues. Other reasons
                are contained in cautionary statements in the Registration Statement on Form
                20-F filed with the U.S. Securities and Exchange Commission, including, without
                limitation, under Item 3.D, "Risk Factors" therein. We do not undertake to
                update any oral or written forward-looking statements that may be made by or on
                behalf of pSivida. </FONT></P>
         <DIV>&nbsp;</DIV>
         <DIV ID="PGBRK"
          STYLE="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
                <DIV ID="FTR">
                  <DIV ID="GLFTR" STYLE="WIDTH: 100%" ALIGN="left"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV>

                <DIV ID="PN">
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt" FACE="Times New Roman"></FONT></DIV>
                  <DIV STYLE="WIDTH: 100%; TEXT-ALIGN: center">
                         <HR COLOR="#000000" NOSHADE="NOSHADE" SIZE="2"> </DIV></DIV>
                <DIV ID="HDR">
                  <DIV ID="GLHDR" STYLE="WIDTH: 100%" ALIGN="right"><FONT
                         STYLE="DISPLAY: inline; FONT-SIZE: 8pt; COLOR: #000000; FONT-FAMILY: Times New Roman"></FONT></DIV></DIV></DIV>
         </BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.gif
M1TE&.#EAC@!&`/<``(RT*SR:F?;Z^H*^O<7AX?/NEOGYV_W]]6.NK>3<,OK\
M_*G2TEVKJN/@4O7TQ'&UM.'>2?_^_)O+RNCF<];2"-;2!;;9V?OZY?S\[8S#
MPL7<L3F9E[_>W=;JZ0J`?D>@GFRSLOCXU]S9*OCWTP)\>MG6&?+X^.[LE?;U
MR.OH?O[^^%.FI<WEY4NBH/7TP:'/SBB0CM#GYC66E09^?/#OI?[^^B6)E?W\
M\'BYN.SKC>?E;>;D:MG5%MC4$=[;..3B7JK0N_W]\^;R\N+7`>KT]*;1T>+?
M3:[5U.GG>N7C8QV*B2",BI#&Q=_N[@Q^A,3AW>;C90V"@._MF^SJBN#MW4:?
MG<'?WM[:-.7B8.OIA;#7UMS9+.[MF>+P[Y[-S?KZXC"4DBR2D.CB2MO8)MWM
M[=O7(]K6'K?:V26.C1J(A^KH@>'>1]_</=W:,LCCXA*$@N#=0#^<F^[LF)?)
MR!6&A/'OJ=?4#_S[Y>[V]G2WM=W9+OO[Z-;2`.#=1$*=G-G3`.SU]>/<+//R
MN//QLV:PK^WKD,/?X7:XMYC*R97(Q^/8"MW5`/S[Z]31`/?VS87`O]?3"S.5
ME.'O[_/RM_S]_?C[^RN1D/[^_@%\>OW^_G^]O`N!?_7Z^OG\_/3Y^0F`?O__
M_=71`JO4T_#W]]72`P-]>_/RM>#O[]CKZ^GT\R^3DJS4T]'GY^3Q\1B'ALOD
MY.3A5^WV]EFIJ'Z\N[38V`=_?>WLD];1`"Z3D>#O[O#NH=;2`KK&$I##NNCE
M:_S]_M_@7QB%B;'6S1V&<UFC;JK1U=[HN.;IF(FU1U>HI^/?4-KJ[N?S\K+6
MV86^PO;RL/3RM?3Y^N3;'=_KU>GMKWR[NJ//S_S]^_W^^=?BF0![>G:UO._V
M[);%J/3WX_C[]]792.?E</7TO#&1CN3A6;O<V]O4!YG*REZ@1KS<U^GC5Z70
MT/O\\2R1DCB3GNK>(NC>+MW6$-[:+,G-">SRV=#EU._NG]/HZ`^#@=K4`/CW
MT/[^__[__M71``![>?___R'Y!```````+`````".`$8```C_`/\)'$BPH,&#
M"!,J7,BPH<.'$"-*G$BQHL6+&#-JW,BQH\>/($.*'$FRI,F3*%.J7,FRI<N7
M,&/*G$FSILV;.'/JW,FSI\^?0(-BY"0*Q!L2+9H(7=KDD*L98`BM\!=@*5`B
M.#8IT70OD\``_JSVI.0ES2=-L0JJLB1VIZ@-_I*A,MC!7X:V.`54\[>)"<('
M)"3AM7D&UXQ#2@^2*95G,$T\VYSX8:&PB@Q.$E5\&1$"0T('(D2,23&1$`Q+
M,%8MO%2I=:5+&AU!"5=H1,$@-W+KSLV.V[0N!`V<"`?%@<!SKA(_U+=#!"0*
M%'BLH7'05+_K/R;Z\<<=T4(A,BQ9_Y(A1&.=Z_T@J1D8P4<_"G;BRS<WY%T-
M@0?4V$%?X%^')1Q$Y$(/Z!78#RP'%#0(>ME)%`=W_LRQT"FE<%?**1K5<$$(
M=530SWK_@,+%#F48V(\(24RA@D`[7"=%"'=@DTD+7D1T0QLF%AA.02CXX&,6
M$SVPP9!:+"3))MQM(MA&A;1!("GB$/0%#P7J<0-!CG@(21ND_>/,`!)-4&`#
M.2!1`GJAH$`0*!&T"<I$F5`B)VP*'9GDDAH9($4A%!RXIAX%0E!0BZ1D(85M
MAM`B40U7H.?#F_^8XN%U.[!D)U]X9M2C#U26<*5`-<A3X!H$J2!"/SWX.$@F
M9!!TQ@(+G/_Q3R5:'/+`'*,0%,29UW4I4`K]\``!=0/M4<>Q:OZ3B06P'M')
M0)F\NL`1"@AD!:P+M$J0`-8<<L@JG!"!)*8%=<)!!@\\@$,1K3STQ0E<K-%/
M!?H,]$T@?*!'ZD`70-*/#UR<8``_!<'`'1BL@`&A/W%X,E`05%Z7!$$8".)9
M0=9=AX5`^WS`'2:L#)3*N&%4^\]VW)U#T"5301@)+6_<25`K8"WL#QT+.(1"
M"240V$^4_Q0#A`_Y7K>O0%FBRC,T!EG"W1).VPS"0#5L@9X==3`T"7H3"S0+
MA.L,Q`&$"`Q4!802$$2+S?Y$48O,`N'Q(-O^O-%!0QC8(T42USW_\X\A3G3#
M1M']'/V/`Z'T@X44]NQA4!@0SO!`(BC[@T\J`]E2("D-)(O0UA(/5`XFW#TP
MT",0OC"0Q]RE+9``,D`HPQS51`&AD@)=P@"$'LC"0,RE-[1'`T:XEP\U3SAA
M`Q4)$&ZX(/V$PH81RH3P.(2)"-3!#!!:,1`H$!@(22&?&@1Z/UW_`PCP?@A$
M2<TSW"T0Z_ZX[A\)W)'@_3\+5$BN^F_CCE_^X072^:-]#`&%+9``BWXL(AL!
M0$,N_A&(41%$%]>!`A)4=#U_E.(5`VD!V`AR@3Z8:`S$*LCYTG>)L]TL+=OC
MCB6>-3^TB0Y":7#8/Y@Q+MS]HPDM^,`'_U:@0R%X@#L;:`@HLH`%+-CA#\`0
MQC+^H0*KZ8L@.NB'&9*`!23<IR"0\R`!!J()&Y8J!7TRT`Z^.)`5$J2,_L"$
M]ZQ!-H+0SWZB<!DE!'(I']*I($T85Q(;,@(L_*!/\?"&0*IH08'LX4PE,*3G
M"!+&4HQ1('"LWT%<`('$%6@"*N2:VB`D(1Q\K$BK,R/_(+2!/?ZCCYD:B``L
MD`<P&'"0#-D#+)2!A38T0@P7`Q1ZC""0()"C'UOX`?$,<)!*7O(?F;2?05Q@
MP@()@B!N',CZN.,'!;C0$B:K8>L&L@!6NA*6!6&&)L*X,%PRY!H%\$4#/#0&
M'4R!5]<100XF</\J4AA!!UE(4#,M],QH*D0%1BA0^OZ1S=S5;!.L4`)W&%"0
M.Y+3G'SL8:8ZH`H(80(7`72G0IH1``U`8!<Y2NEUC.`"2'70DF14I4`PP,R!
MW*":_=##B@324*]9*`_XX(Z$[*C*<B+QG!H=B!8D&D<&6"&02&P("_`1C`D:
M0`Y08$,9>N#)ZU2@!V5@`Q9L81N%.',@`S`C"G30!QZ4X&("6=!US!"$-HJ2
M(%"U7(5*$8.*%A6CKTSJ/TYA.P$*I!6"9$@KT!`%RJSI`(PX%7KZ<(,#N'0A
M9Q7(`\QX@@)E;2#GN4X9!,K0NQ($+@M;`F:(.DZ!:`%"X!1(%P2;"`C_34T@
M0DCL0F01(81$P(K7$11$PDB"2U8"#1`Z@D#NX+-^E,%Z_S"`,`OGTIX*Q)0+
MHZA?6_L/`N"O;<PX["?@1@@(E6,@KPCI0E!7-H0P\HH"^45#V"D+0%"B"!`B
M05\%DD7TF"$')QA#@::`3=,.)(\+&R!K-7G8(PJ0$J,`P>V6A``($<($"F!%
M)%BID`SX8P,Z/,A[KR.&?W`B!KEB"#O]D089C,L?:!#`P\*GTC$XSJZA*\BE
M/.@&@U@T=Q7F3BTVL`2^P`UU$$(#&+C'8818H11OF$M"1CP$<*3#&L"9+W<^
M,;>%Y8P@C'!/CD10UH%DK!\-6EGLN),&&1>D_W+>&0@9QKLP0@3Y0@)!!9,7
MUH)QJ0(A>(!!%,Y[4*O=8@B\($81HO&0,,Z``"_8P`Q*D08%DY"?%`A%!2"Q
M!21<P""@"8VO"#*`TUCBM@4AA'@LH1J"O&`),YC!$G!0B4>(ASP#*0(8:D$"
M#\@@`Z/X@'BJ@)`RWF4A5?S#$``P#BI$I)(]I@0KW`"(@QK``2CXPDX-`@H5
M>)N-*W.-5PRB`->XDB">B`$+3""0<K?FC__HQ#T(0`97NKL2!V$&'9:`!X9$
M`![S0$<5-)`"<*N8H([!2%I5QQ!N(&,8O3"&--CP;(0GO"*=0`,:\*V03IS#
M!NZHQS$4<0LX5%R,%[:O"![\`::$9.((D7`"$.BACD5<AP([F((N#(X0Y'+'
M$"F?B`D\$88:(80%<=!&.ZB0`T40#CV0J"M#&#"D`-PCZ!*)@0+<T&.#N`$!
MW$,`(()0`#E(X>QHYP(->([UCJR`"`8QP1%$R+``M?TE_O@``3SAB0XL``1,
ME<7^[OZ2EJ6!#A":]=4)'Y-4R((.GTC#!W!0CM4R_O*8S[SF-\_YSGO^\Z`/
2O>A'3_K2F_[TJ$^]ZED2$``[
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
